Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 3/2016

01-04-2016 | Original Article

18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes

Authors: Sampanna Jung Rayamajhi, Bhagwant Rai Mittal, Venkata Nagarjuna Maturu, Ritesh Agarwal, Amanjit Bal, Pranab Dey, Jaya Shukla, Dheeraj Gupta

Published in: Annals of Nuclear Medicine | Issue 3/2016

Login to get access

Abstract

Purpose

There is currently no single modality for accurate characterization of enlarged mediastinal lymph nodes into benign or malignant. Recently 18F-fluorothymidine (FLT) has been used as a proliferation marker. In this prospective study, we examined the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and 18F-FLT PET/CT in categorizing mediastinal lymph nodes as benign or malignant.

Materials and methods

A total of 70 consecutive patients with mediastinal lymphadenopathy detected on computed tomography (CT) or chest radiograph underwent whole body 18F-FLT PET/CT and 18F-FDG PET/CT (within 1 week of each other). Lymph nodal tracer uptake was determined by calculation of standardized uptake value (SUV) with both the tracers. Results of PET/CT were compared with histopathology of the lymph nodes.

Results

Histopathology results showed thirty-seven patients with sarcoidosis, seven patients with tuberculosis, nine patients with non-small cell lung cancer, five patients with Hodgkin’s lymphoma and twelve patients with non-Hodgkin’s lymphoma. The mean FDG SUVmax of sarcoidosis, tuberculosis, Hodgkin’s and non-Hodgkin’s lymphoma was 12.7, 13.4, 8.2, and 8.8, respectively, and the mean FLT SUVmax was 6.0, 5.4, 4.4, and 3.8, respectively. It was not possible to characterize mediastinal lymphadenopathy as benign or malignant solely based on FDG SUVmax values (p > 0.05) or FLT SUVmax values (p > 0.05). There was no significant difference in FDG uptake (p > 0.9) or FLT uptake (p > 0.9) between sarcoidosis and tuberculosis. In lung cancer patients, the FDG SUVmax and FLT SUVmax of those lymph nodes with tumor infiltration on biopsy was 6.7 and 3.9, respectively, and those without nodal infiltration was 6.4 and 3.7, respectively, and both the tracers were not able to characterize the nodal status as malignant or benign (p > 0.05).

Conclusion

Though 18F-FLT PET/CT and 18F-FDG PET/CT reflect different aspects of biology, i.e., proliferation and metabolism, respectively, neither tracer could provide satisfactory categorization of benign and malignant lymph nodes. The results of this study clearly suggest that differentiation of mediastinal nodes into benign and malignant solely based on SUVmax values cannot be relied upon, especially in settings where tuberculosis and sarcoidosis are common.
Literature
1.
Goodwin RA, Shapiro JL, Thurman GH, Thurman SS, Des Prez RM. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore). 1980;59(1):1–33.CrossRef
2.
Sagel SS. Common fungal diseases of the lungs. I. Coccidioidomycosis. Radiol Clin North Am. 1973;11(1):153–61.PubMed
3.
Manns BJ, Baylis BW, Urbanski SJ, Gibb AP, Rabin HR. Paracoccidioidomycosis: case report and review. Clin Infect Dis. 1996;23(5):1026–32.CrossRefPubMed
4.
Petrillo R, Balzarini L, Bidoli P, Ceglia E, D’Ippolito G, Tess JD, et al. Esophageal squamous cell carcinoma: MRI evaluation of mediastinum. Gastrointest Radiol. 1990;15(4):275–8.CrossRefPubMed
5.
Zerhouni EA, Rutter C, Hamilton SR, Balfe DM, Megibow AJ, Francis IR, et al. CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology. 1996;200(2):443–51.CrossRefPubMed
6.
Sohn KM, Lee JM, Lee SY, Ahn BY, Park SM, Kim KM. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol. 2000;174(6):1551–7.CrossRefPubMed
7.
Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology. 1998;207(1):123–30.CrossRefPubMed
8.
Puri SK, Fan CY, Hanna E. Significance of extracapsular lymph node metastases in patients with head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2003;11(2):119–23.CrossRefPubMed
9.
Savage C, Zwischenberger JB. Image-guided fine needle aspirate strategies for staging of lung cancer. Clin Lung Cancer. 2000;2(2):101–10 (discussion 11–12).CrossRefPubMed
10.
Milman N, Faurschou P, Munch EP, Grode G. Transbronchial lung biopsy through the fibre optic bronchoscope. Results and complications in 452 examinations. Respir Med. 1994;88(10):749–53.CrossRefPubMed
11.
Pereira W Jr, Kovnat DM, Snider GL. A prospective cooperative study of complications following flexible fiberoptic bronchoscopy. Chest. 1978;73(6):813–6.CrossRefPubMed
12.
Varela-Lema L, Fernandez-Villar A, Ruano-Ravina A. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J. 2009;33(5):1156–64.CrossRefPubMed
13.
Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409–15.CrossRefPubMed
14.
Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 2001;42(5):721–5.PubMed
15.
Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54(6):903–12.CrossRefPubMed
16.
Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):236–45.CrossRefPubMed
17.
Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D, et al. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2010;37(7):1291–9.CrossRefPubMed
18.
Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med. 2008;49(2):186–94.CrossRefPubMed
19.
Hoshikawa H, Kishino T, Mori T, Nishiyama Y, Yamamoto Y, Inamoto R, et al. Comparison of (18) F-FLT PET and (18) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers. Acta Otolaryngol. 2012;132(12):1347–54.CrossRefPubMed
20.
Schaefferkoetter JD, Carlson ER, Heidel RE. Can 3′-deoxy-3′-((18)F) fluorothymidine out perform 2-deoxy-2-((18)F) fluoro-d-glucose positron emission tomography/computed tomography in the diagnosis of cervical lymphadenopathy in patients with oral/head and neck cancer? J Oral Maxillofac Surg. 2015;73(7):1420–8.CrossRefPubMed
21.
Nakajo M, Kajiya Y, Jinguji M, Nishimata N, Shimaoka S, Nihara T, et al. Diagnostic performance of (1)(8)F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with (1)(8)F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging. 2013;40(8):1223–32.CrossRefPubMed
22.
Kumar A, Dutta R, Kannan U, Kumar R, Khilnani GC, Gupta SD. Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med. 2011;6(1):11–6.CrossRefPubMedPubMedCentral
23.
Al-Sarraf N, Aziz R, Doddakula K, Gately K, Wilson L, McGovern E, et al. Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography. Interact CardioVasc Thorac Surg. 2007;6(3):350–3.CrossRefPubMed
24.
Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer. 2005;47(2):235–42.CrossRefPubMed
25.
26.
Sobic-Saranovic DP, Grozdic IT, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko VM, Saranovic DZ, et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med. 2013;38(7):516–21.CrossRefPubMed
27.
Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543–9.CrossRefPubMed
28.
Maturu VN, Agarwal R, Aggarwal AN, Mittal BR, Bal A, Gupta N, et al. Dual-time point whole-body 18F-fluorodeoxyglucose PET/CT imaging in undiagnosed mediastinal lymphadenopathy: a prospective study of 117 patients with sarcoidosis and TB. Chest. 2014;146(6):e216–20.CrossRefPubMed
29.
Chilosi M, Menestrina F, Capelli P, Montagna L, Lestani M, Pizzolo G, et al. Immunohistochemical analysis of sarcoid granulomas. Evaluation of Ki67+ and interleukin-1+ cells. Am J Pathol. 1988;131(2):191–8.PubMedPubMedCentral
30.
Semenzato G, Pezzutto A, Pizzolo G, Chilosi M, Ossi E, Angi MR, et al. Immunohistological study in sarcoidosis: evaluation at different sites of disease activity. Clin Immunol Immunopathol. 1984;30(1):29–40.CrossRefPubMed
31.
Tan Y, Liang J, Liu D, Zhu F, Wang G, Ding X, et al. F-FLT PET/CT imaging in a Wister rabbit inflammation model. Exp Ther Med. 2014;8(1):69–72.PubMedPubMedCentral
32.
Zhao S, Kuge Y, Kohanawa M, Takahashi T, Zhao Y, Yi M, et al. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT. J Nucl Med. 2008;49(1):135–41.CrossRefPubMed
33.
Wang R, Zhu H, Chen Y, Li C, Li F, Shen Z, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. Hematol Oncol. 2014;32(3):126–32.CrossRefPubMed
34.
Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66(22):11055–61.CrossRefPubMed
35.
Sharma SK, Mohan A. Sarcoidosis in India: not so rare! JIACM. 2004;5(1):12–21.
Metadata
Title
18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes
Authors
Sampanna Jung Rayamajhi
Bhagwant Rai Mittal
Venkata Nagarjuna Maturu
Ritesh Agarwal
Amanjit Bal
Pranab Dey
Jaya Shukla
Dheeraj Gupta
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 3/2016
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-1047-6

Other articles of this Issue 3/2016

Annals of Nuclear Medicine 3/2016 Go to the issue

Original Article

Development of a simple non-invasive microsphere quantification method for cerebral blood flow using I-123-IMP

Case Report

FDG PET/CT allowing detection and follow-up of tumor cell transplantation

Original Article

Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?

Original Article

Prognostic value of PET/CT with 18F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy

Short Communication

A descriptive analysis of remnant activity during 90Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications

Original Article

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma